Related Experiment Videos
A review of the adverse events profile of cefpirome
E Rubinstein1, R Labs, A Reeves
1Tel Aviv University School of Medicine, Israel.
Abstract:
Cefpirome is a new fourth generation injectable cephalosporin antibiotic. Its tolerability profile was established in a programme of 16 clinical studies involving 3103 patients in Europe and the US. The overall incidence of clinical adverse events with cefpirome was 21.9% compared with 27.1% with comparators (ceftazidime, imipenem, ceftriaxone). Adverse events thought possibly related to treatment occurred in 12.5% of patients receiving cefpirome and 13.7% of recipients of comparator agents. Withdrawals from treatment due to adverse events occurred in 5.1 and 5.0% of patients receiving cefpirome and comparators, respectively. The commonest adverse events thought possibly related to treatment were gastrointestinal symptoms (mainly diarrhoea in 1.6 and 1.7%, respectively) and rash (1.4 and 1.4%, respectively). Comparison with data obtained from the literature for ceftazidime, ceftriaxone and the third generation cephalosporins in general shows that the adverse event profile of cefpirome is similar to that of other broad-spectrum injectable cephalosporins.
Insights
Cefpirome, a fourth-generation cephalosporin antibiotic, demonstrates a favorable tolerability profile. Its adverse event incidence is comparable to other broad-spectrum injectable cephalosporins, indicating good patient safety.
Area of Science:
- Pharmacology
- Clinical Medicine
- Infectious Diseases
Background:
- Cefpirome represents a novel fourth-generation injectable cephalosporin antibiotic.
- Understanding the tolerability of new antibiotics is crucial for clinical adoption and patient safety.
Purpose of the Study:
- To establish the tolerability profile of cefpirome.
- To compare the adverse event incidence of cefpirome with established comparator antibiotics.
Main Methods:
- A comprehensive clinical trial program involving 3103 patients across Europe and the US.
- Systematic collection and analysis of clinical adverse events and treatment withdrawals.
- Comparison of cefpirome's adverse event data with comparator agents (ceftazidime, imipenem, ceftriaxone) and literature data.
Main Results:
- Overall clinical adverse events occurred in 21.9% of cefpirome recipients versus 27.1% for comparators.
- Adverse events possibly related to treatment were observed in 12.5% for cefpirome and 13.7% for comparators.
- Treatment withdrawals due to adverse events were similar for cefpirome (5.1%) and comparators (5.0%).
- Gastrointestinal symptoms and rash were the most common related adverse events for both cefpirome and comparators.
Conclusions:
- Cefpirome exhibits a favorable tolerability profile in a large patient population.
- The adverse event profile of cefpirome is similar to other broad-spectrum injectable cephalosporins, including third and fourth-generation agents.
- Cefpirome is a well-tolerated option among injectable cephalosporin antibiotics.